TY - JOUR T1 - An interpretable mortality prediction model for COVID-19 patients – alternative approach JF - medRxiv DO - 10.1101/2020.06.14.20130732 SP - 2020.06.14.20130732 AU - Peter Gemmar Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/22/2020.06.14.20130732.abstract N2 - The pandemic spread of coronavirus leads to increased burden on healthcare services worldwide. Experience shows that required medical treatment can reach limits at local clinics and fast and secure clinical assessment of the disease severity becomes vital. In [1] a model is presented for predicting the mortality of COVID-19 patients from their biomarkers. Three biomarkers have been selected by ranking with a supervised Multi-tree XGBoost classifier. The prediction model is built up as a binary decision tree with depth three and achieves AUC scores of up to 97.84±0.37 and 95.06± 2.21 for training and external test data sets, resp.In human assessment and decision making influencing parameters usually aren’t considered as sharp numbers but rather as Fuzzy terms [2], and inferencing primarily yields Fuzzy terms or continuous grades rather than binary decisions. Therefore, I examined a Sugenotype Fuzzy classifier [3] for disease assessment and decision support. In addition, I used an artificial neural network (SOM, [4]) for selecting the biomarkers. Modelling and validation was done with the identical data base provided by [1]. With the complete training and test data sets, the Fuzzy prediction model achieves improved AUC scores of up to 98.59 or 95.12 The improvements with the Fuzzy classifier obviously become clear as physicians can interpret output grades to belong to positive or negative class more or less strongly. An extension of the Fuzzy model, which takes into account the trend in key features over time, provides excellent results with the training data, which, however, could not be finally verified due to the lack of suitable test data. The generation and training of the Fuzzy models was fully automatic and without additional adjustment with the help of ANFIS from Matlab©.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBasically, all data for feature analysis as well as for training and testing the classifiers have been taken from the original data base provided by L. Yan et al. ER -